BRÈVE

sur INTRASENSE (EPA:ALINS)

Intrasense and Guerbet Secure PMDA Certification in Japan for DUOnco™ Pancreas

Graphique de l'évolution du cours de l'action INTRASENSE (EPA:ALINS).

Montpellier, Villepinte, June 8th 2026 - Intrasense, a French AI medical imaging specialist, and Guerbet, a global leader in medical imaging, announce PMDA certification for DUOnco™ Pancreas in Japan. This AI software is the first of its kind in Japan, assisting in reading pancreatic areas on CT scans.

With pancreatic cancer being a major health challenge in Japan, early detection is crucial. Studies indicate that CT findings of pancreatic cancer can appear up to 36 months before diagnosis. DUOnco™ Pancreas aims to enhance radiologists' ability to detect these early signs by highlighting regions of interest in the pancreas during contrast-enhanced CT exams.

This certification marks a significant step in the international expansion of DUOnco™ Pancreas, complementing its CE mark in Europe and Breakthrough Device designation by the FDA. Intrasense and Guerbet strive to integrate the software smoothly into radiologists' work environments in collaboration with local IT partners.

R. E.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de INTRASENSE